Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Teva Rises Most in Month on Lipitor Speculation, P&G Venture

Nov. 3 (Bloomberg) -- Teva Pharmaceutical Industries Ltd. rose the most in more than a month on speculation it may start selling a generic of Pfizer Inc.’s Lipitor anti-cholesterol pill and as it formed a partnership with Procter & Gamble Co.

The shares of the world’s largest generic drugmaker climbed 5.2 percent, the biggest increase since Oct. 2, to 149.10 shekels, at the 4:30 p.m. close in Tel Aviv.

Teva said yesterday that if it manages to introduce an “important undisclosed product” in the fourth quarter, it would meet the upper range of its forecast of earnings excluding some costs of $4.92 to $5.02 a share this year.

“This is ostensibly Lipitor,” Sanford C. Bernstein & Co. analysts led by Ronny Gal wrote in a report late yesterday. “What other product can give Teva 10 cents of earnings per share or $89 million net income in one month?”

Separately, Teva and Procter & Gamble said a new consumer-health care partnership “has the potential to reach double-digit sales growth and $4 billion in sales towards end-of-decade.”

Also, Morgan Stanley raised its recommendation on Teva to “overweight” from “equal weight.”

To contact the reporters on this story: Shoshanna Solomon in Tel Aviv at; Naomi Kresge in Berlin at

To contact the editor responsible for this story: Claudia Maedler at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.